Roivant Sciences

ROIV

Market cap $14B

Roivant Sciences Ltd. ( ROIV ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good afternoon.

ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1H2026. Plus, it can target NIU and CS.

Roivant Sciences Ltd. ( ROIV ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST Company Participants Richard Pulik - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right.

Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Samantha Semenkow - Citigroup Inc., Research Division Yaron Werber - TD Cowen, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yuchen Ding - Jefferies LLC, Research Division Dominic Risso-Gill Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27.

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints in Phase 3 VALOR study in dermatomyositis (DM), with NDA filing planned for the first half of calendar year 2026 Brepocitinib program continues to advance with rapid enrollment in Phase 3 study in non-infectious uveitis (NIU) and proof-of-concept trial in cutaneous sarcoidosis (CS), with readouts expected in the first half of calendar year 2027 and second half of calendar year 2026, respectively Immunovant study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data.

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.

BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025, and provide a business update.

Roivant Sciences Ltd. (NASDAQ:ROIV ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I cover U.S. biotech at Bernstein.

Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division We're at time.